News from ARMAGEN A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 08, 2015, 07:00 ET
ArmaGen aims to transform the treatment of severe neurological disorders by engineering and developing revolutionary therapies for the brain.

ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome

 ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced...

Mar 17, 2015, 07:00 ET
ArmaGen aims to transform the treatment of severe neurological disorders by engineering and developing revolutionary therapies for the brain.

ArmaGen to Present at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference

 ArmaGen, a privately held biotechnology company focused on developing revolutionary therapies to treat severe neurological disorders,...

Dec 11, 2014, 07:00 ET
ArmaGen aims to transform the treatment of severe neurological disorders by engineering and developing revolutionary therapies for the brain.

ArmaGen Announces FDA Acceptance of IND Application for AGT-182 for the Treatment of Hunter Syndrome

ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today...

Dec 03, 2014, 07:00 ET
ArmaGen aims to transform the treatment of severe neurological disorders by engineering and developing revolutionary therapies for the brain.

ArmaGen to Present at Oppenheimer 25th Annual Healthcare Conference

ArmaGen, a privately held biotechnology company focused on developing revolutionary therapies to treat severe neurological disorders, announced...

Jul 23, 2014, 07:00 ET
ArmaGen. (PRNewsFoto/ArmaGen)

ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome

 ArmaGen, a privately held biotechnology company focused on developing revolutionary therapies to treat severe neurological disorders,...

Sep 04, 2013, 09:00 ET

ARMAGEN® Expands Patent Portfolio With Issuance Of Two Additional U.S. Patents

ARMAGEN, a leader in the field of transporting therapeutics across the blood brain barrier (BBB) today announced the issuance of two additional...

Jul 18, 2013, 13:22 ET

ARMAGEN® Receives US Orphan Designation For Lead Product AGT-182

 ARMAGEN announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead product AGT-182 for...

Jan 03, 2013, 19:14 ET

ArmaGen Technologies, Inc. Hires Biotech Executive as CEO

ArmaGen Technologies, Inc., a leader in the delivery of biotherapeutics targeting the central nervous system (CNS), today announced James Callaway,...

Nov 29, 2012, 19:39 ET

ArmaGen Technologies, Inc. Announces $17 Million Series A Financing

 ArmaGen Technologies, Inc. today announced the closing of a $17 million Series A financing to support the development of brain-penetrating...

Jul 16, 2010, 18:32 ET

ArmaGen® Re-engineers Erythropoietin for Brain Penetration

Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and...